We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Jan 2020
  • Code : CMI3364
  • Pages : 167
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Physical or psychological factors both can result into sexual dysfunction. In most cases issues with sexual health result from a combination of physical and psychological factors. It is a common health problem in both men and women. Delayed ejaculation, premature ejaculation, and inability to achieve full erection are some common sexual dysfunction symptoms in men, while symptoms such as vaginal dryness, dyspareunia are observed in women. Sexual dysfunction is categorized into four main types including desire disorders, arousal disorders, orgasm disorders, and pain disorders. These conditions can be well treated with drugs such as erectile dysfunction drugs, gender dysphoria drugs, hypoactive sexual desire disorder drugs, and premature ejaculation drugs.

The global sexual health market is estimated to be valued at US$ 10,697.3 million in 2019, and is expected to exhibit a CAGR of 4.2% during the forecast period (2019–2027).

Figure 1. Global Sexual Health Market Share (%), By Product Type, (2019 & 2027)

SEXUAL HEALTH MARKET

Source: Coherent Market Insights Analysis (2019)

Increasing research and development activities by key players are expected to drive growth of the market over the forecast period

Rising involvement of major players in development of novel, and effective drug candidates for treatment of sexual dysfunction is likely to contribute to the growth of the sexual health market. For instance, in November 2019, Can-Fite BioPharma Ltd. received a patent grant in Canada, South Korea, and Israel for its drug candidate CF602, for the treatment of a sexual dysfunction.

Furthermore, increasing drug approvals from regulatory authorities and product launches are expected to drive the market growth. For instance, in November 2014, Sandoz, the generic pharmaceuticals division of Novartis, launched Vitaros, an innovative topical therapy for erectile dysfunction (ED), in Sweden.

Global Sexual Health Market- Restraints

Number of side effects such as long-lasting erection, facial flushing, visual changes, and hearing loss among others caused by using drugs for treating sexual dysfunctions may hamper consumer demand and growth of the market. Furthermore, increasing cases of undiagnosed or untreated sexual health issues may hinder the market growth.

Global Sexual Health Market- Regional Analysis

Regional segmentation of the global sexual health market includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is estimated to exhibit significant growth in the sexual health market owing to adoption of inorganic growth strategies by key players to launch drugs in the region. For instance, in the fourth quarter of 2015, Valeant Pharmaceuticals International, Inc. acquired Sprout Pharmaceuticals, Inc. In August 2015, Sprout Pharmaceuticals, Inc. received U.S. FDA approval for its New Drug Application (NDA) for flibanserin. Following the acquisition of Sprout Pharmaceuticals, Inc., Valeant Pharmaceuticals has introduced the flibanserin (Addyi) in the U.S. market.

Figure 2: Global Sexual Health Market Share (%), By Region, (2019 & 2027)

SEXUAL HEALTH MARKET

Source: Coherent Market Insights Analysis (2019)

Global Sexual health Market- Competitive Landscape

Key players operating in the sexual health market include Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca.

Frequently Asked Questions

The global sexual health market is estimated to reach US$ 14.1 Billion by 2027.

Major players operating in the global sexual health market include Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca.

Number of side effects associated with drugs for treating sexual dysfunctions such as long-lasting erection, facial flushing, and hearing loss among others is the major factor that is expected to hamper growth of the market over the forecast period.

Rising number of drug approvals from regulatory authorities and product launches are some of the major factors that are expected to propel growth of the market over the forecast period.

The global sexual health market is estimated to exhibit a CAGR of 4.2% over the forecast period (2019-2027).

Increasing number of clinical trials by key players for developing novel treatment option for treating sexual dysfunctions is one of the major trends that has been observed in the market.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo